Frank Wang, MBA

Co-founder, Chief Executive Officer

Mr. Frank Wang is SCG’s Co-founder, CEO and Managing Director. Mr. Wang is a serial entrepreneur with over 20 years of experience in strategic planning and international enterprise management. Before joining SCG, he co-founded BioSyngen Pte. Ltd. and served as its Chairman and Chief Executive Officer. Frank received his B.S from Harbin Institute of Technology in China and MBA from Roosevelt University in the United States.

Ke Zhang, PhD

Chief Scientific Officer

Dr. Ke Zhang is SCG’s Chief Scientific Officer and a member of the Board of Directors. Before joining SCG, Dr. Zhang acted as the principal project leader at Janssen/Johnson & Johnson R&Dand led several innovative projects. He has received the EASL Young Researcher Award. Dr. Zhang earned his PhD in Molecular Medicine at Faculty of Medicine, Technical University of Munich and received his postdoc training at Institute of Medical Virology, German National Research Center for Environmental Health.

Christy Ma, MS

Chief Strategy Officer

Ms. Christy Ma is SCG’s Chief Strategy Officer and a member of the Board of Directors. Ms. Ma specializes in oncology and immunotherapy drug development. Before joining SCG, she served in various positions in Clinical Operations and Pharmacovigilance at Genentech, BioMarin and Five Prime Therapeutics Inc., with participation in the development of Talzenna® (talazoparib), Cabiralizumab in combination with Opdivo® (nivolumab), Herceptin® (trastuzumab) and Avastin® (bevacizumab). Christy received a B.S. degree in Chemical Biology from the University of California, Berkeley and her M.S. in Medical Product Development Management from San Jose State University. 

Karin Wisskirchen, PhD

Head of Research, SCG Germany

Dr. Wisskirchen heads SCG’s early research efforts and is also a postdoctoral fellow at the Institute of Virology in Munich. She is a leading expert in the field of adoptive T cell therapy of chronic hepatitis B and HBV-induced hepatocellular carcinoma and has received numerous honors and awards, such as the "GASL price of the YAEL foundation" in 2020, the twice the "Young Investigator Award" of the International Society for Cellular Therapy.  Dr. Wisskirchen received her PhD in virology from Technical University of Munich and her diploma in Biology from the Philipps University of Marburg.

Wolfgang Uckert, PhD

Chief Innovation Officer

Dr. Wolfgang Uckert is SCG’s Chief Innovation Officer.  Dr. Uckert is one of the pioneering scientists in cell therapy and the inventor of a high affinity TCR screening technology platform.He spent nearly 40 years in the field of genetic and molecular cell biology research and was rated the top 0.5% expert of cell therapy by Expertscape.  
Dr. Uckert was a Former Director of the Institute for Cell, Molecular Biology and Gene Therapy, Center for Molecular Medicine, University of Berlin, Germany. 

Maggie Gu, MD

 Chief Medical Officer

Dr Maggie Gu is SCG’s Chief Medical Officer, brings over more than 20 years of experience in drug development, specializing in oncology. Before joining SCG, Dr Gu held key executive positions at pharmaceutical and biotech companies, including serving as the China General Manager of Immune-Onc Therapeutics, VP of the Shanghai Innovation Hub at Ipsen, VP of Clinical Development at Shanghai Junshi, and Senior Director of Clinical Operations at AstraZeneca China/Hong Kong, along with the role of Clinical Operations and Therapeutic Medical Director at GlaxoSmithKline China. Dr Gu played a pivotal role in the successful clinical development and NDA/BLA for the first domestic PD-1 antibody Tuoyi®, the third-generation EGFR inhibitor Osimertinib®, and the PARP inhibitor Olaparib®. She holds a master's degree in paediatric clinical medicine from Shanghai Medical University.